{"id":"cyb003","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Anxiety during acute dosing"},{"rate":null,"effect":"Transient perceptual changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CYB003 combines a proprietary formulation of psilocybin with structured psychological support to promote therapeutic breakthroughs in treatment-resistant conditions. The psilocybin acts as a serotonin 5-HT2A receptor agonist, increasing neural connectivity and reducing rigid thought patterns, while the psychological intervention leverages this neuroplastic window to address underlying psychiatric pathology.","oneSentence":"CYB003 is a psilocybin-assisted therapy designed to enhance psychological treatment outcomes in psychiatric conditions by facilitating neuroplasticity and emotional processing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:14.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression (Phase 3)"}]},"trialDetails":[{"nctId":"NCT06564818","phase":"PHASE3","title":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","status":"RECRUITING","sponsor":"Cybin IRL Limited","startDate":"2024-12-17","conditions":"Major Depressive Disorder","enrollment":220},{"nctId":"NCT06793397","phase":"PHASE3","title":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","status":"RECRUITING","sponsor":"Cybin IRL Limited","startDate":"2025-12-10","conditions":"Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder","enrollment":330},{"nctId":"NCT06605105","phase":"PHASE3","title":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","status":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","startDate":"2025-07-18","conditions":"Major Depressive Disorder","enrollment":468},{"nctId":"NCT06820723","phase":"PHASE2","title":"A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety","status":"NOT_YET_RECRUITING","sponsor":"Ohio State University","startDate":"2025-11","conditions":"Depression, Anxiety, Major Depressive Disorder","enrollment":40},{"nctId":"NCT05385783","phase":"PHASE1, PHASE2","title":"A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder","status":"COMPLETED","sponsor":"Cybin IRL Limited","startDate":"2022-08-02","conditions":"Major Depressive Disorder","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CYB003","genericName":"CYB003","companyName":"Cybin IRL Limited","companyId":"cybin-irl-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CYB003 is a psilocybin-assisted therapy designed to enhance psychological treatment outcomes in psychiatric conditions by facilitating neuroplasticity and emotional processing. Used for Treatment-resistant depression (Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}